Drugs / CELMOLEUKIN
CELMOLEUKIN
also known as
hIL-2 · Celeuk · Celmoleukina · Celmoleukine · Interleukin 2 (human) · Rh-polypeptide-25
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03338777 | Feb 2020 | melanoma | Hospital Italiano de Buenos Aires | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03119025 Background | May 2015 → Feb 2018 | chronic hepatitis C virus infection | Russian Academy of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CELMOLEUKIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108176 ↗ |
| Known as | Celeuk | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108176 ↗ |
| Known as | Celmoleukina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108176 ↗ |
| Known as | Celmoleukine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108176 ↗ |
| Known as | hIL-2 | “adjuvant subcutaneous injection of recombinant hIL-2 (250 000 IU)” NCT03119025 ↗1“Lipoplexes carrying hIL-2 and hGM-CSF genes (0.5 mg each)” NCT03338777 ↗ |
| Known as | Interleukin 2 (human) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108176 ↗ |
| Known as | Rh-polypeptide-25 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108176 ↗ |
| Modality | Protein / enzyme biologic | “recombinant hIL-2” NCT03119025 ↗ |
| Route | Subcutaneous | “subcutaneous injection of recombinant hIL-2” NCT03119025 ↗ |